Literature DB >> 26110882

Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.

Rahul R Parikh1, Michael L Grossbard2, Louis B Harrison3, Joachim Yahalom4.   

Abstract

The purpose of this study was to use the National Cancer Database to examine the association between radiation therapy (RT) and overall survival (OS) in early-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) using standard and propensity score (PS)-adjusted Cox proportional hazards models. From 1998-2011, 1915 patients with stage I/II NLPHL were studied, with a median follow-up of 6.6 years (median age = 44). Of the cohort, 1224(64%) received RT (alone or with chemotherapy) to a median dose of 30.6 Gy. Patients were more likely to receive RT if male, younger age, lower stage, no "B"-symptoms, favorably insured, and treatment at comprehensive centers (all p < 0.05). Patients administered RT had an improved 5-year OS (HR = 0.62; 95%CI, 0.43-0.89, p = 0.01). After PS-matching (n = 868) based on all known co-variates, RT use trended towards improved OS (HR = 0.49; 95%CI, 0.23-1.05, p = 0.06). This study represents one of the largest prospective datasets examining the role of RT for stage I/II NLPHL and inclusion of RT may be considered.

Entities:  

Keywords:  Lymphocyte-predominant Hodgkin lymphoma; National Cancer Database; overall survival; radiotherapy

Year:  2015        PMID: 26110882      PMCID: PMC5593757          DOI: 10.3109/10428194.2015.1065978

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  39 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.

Authors:  C Jackson; B Sirohi; D Cunningham; A Horwich; K Thomas; A Wotherspoon
Journal:  Ann Oncol       Date:  2010-03-23       Impact factor: 32.976

3.  A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease.

Authors:  A Aviles; S Delgado
Journal:  Clin Lab Haematol       Date:  1998-04

4.  Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.

Authors:  S Bodis; M D Kraus; G Pinkus; B Silver; M E Kadin; G P Canellos; L N Shulman; N J Tarbell; P M Mauch
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

5.  Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.

Authors:  Andrew Wirth; Kally Yuen; Michael Barton; Daniel Roos; Kumar Gogna; Gary Pratt; Craig Macleod; Sean Bydder; Graeme Morgan; David Christie
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

6.  Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?

Authors:  S Laskar; T Gupta; S Vimal; M A Muckaden; T K Saikia; S K Pai; K N Naresh; K A Dinshaw
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.

Authors:  Maja V Maraldo; Marianne C Aznar; Ivan R Vogelius; Peter M Petersen; Lena Specht
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-29       Impact factor: 7.038

8.  Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases.

Authors:  V I Pappa; A J Norton; R K Gupta; A M Wilson; A Z Rohatiner; T A Lister
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

9.  Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Ranjana H Advani; Sandra J Horning; Richard T Hoppe; Sarah Daadi; John Allen; Yasodha Natkunam; Nancy L Bartlett
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

10.  Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.

Authors:  Shihab Ali; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2013-11-12
View more
  3 in total

1.  Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.

Authors:  Phoebe T M Cheng; Diego Villa; R Petter Tonseth; David W Scott; Alina S Gerrie; Ciara L Freeman; Tom Pickles; Andrea C Lo; Pedro Farinha; Jeffrey W Craig; Graham W Slack; Randy D Gascoyne; François Bénard; Don Wilson; Brian Skinnider; Joseph M Connors; Laurie H Sehn; Kerry J Savage
Journal:  Blood Adv       Date:  2021-09-28

Review 2.  The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Authors:  Santosha Vardhana; Anas Younes
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

3.  Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.

Authors:  Saad Akhtar; M Shahzad Rauf; Yasser Khafaga; Amani Al-Kofide; Tusneem Ahmed M Elhassan; Mahmoud A Elshenawy; Juzer Nadri; Ali Hassan Mushtaq; Nasir Bakshi; Mohammed Shamayel; Suleiman Al-Sweedan; Sohail Sarwar; Irfan Maghfoor
Journal:  BMC Cancer       Date:  2021-04-01       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.